Press release
Why Are Pharmaceutical Companies Investing Heavily in Inflammatory Diseases Biologics Market 2025-2033?
Inflammatory Diseases Biologics Market Size 2025
Download Free Sample Report (Get Higher Priority for Corporate Email ID):- https://datamintelligence.com/download-sample/inflammatory-diseases-biologics-market?kb
United States: Recent Industry Developments
✅ March 2026: AbbVie Inc. expanded immunology biologics manufacturing capacity to support rising demand for advanced inflammatory disease therapies across North America.
✅ February 2026: Amgen Inc. advanced clinical development programs for next-generation biologics targeting rheumatoid arthritis and inflammatory bowel diseases.
✅ January 2026: Johnson & Johnson strengthened investments in biologic therapies focused on psoriasis and ulcerative colitis treatment innovation.
✅ December 2025: Pfizer Inc. enhanced R&D collaborations for monoclonal antibody therapies aimed at chronic inflammatory and autoimmune disorders.
Ready to scale in the Inflammatory Diseases Biologics Market? connect with the right partners and unlock new growth opportunities today:- https://www.datamintelligence.com/partner-identification-enquiry/inflammatory-diseases-biologics-market?kb
List of Key Players 2026:
Amgen Inc., Novartis Pharmaceuticals Corporation, Johnson & Johnson, Pfizer Inc., F. Hoffmann-La Roche Ltd, GSK, AbbVie, Sanofi, Eli Lilly and Company, and Takeda Pharmaceuticals U.S.A., Inc
Key Strategic Growth Forecast Projections 2026:
The Global Inflammatory Diseases Biologics Market is entering a high-growth phase, with strong momentum expected throughout 2026-2033. Backed by accelerating industry adoption, strategic investments, and continuous innovation from leading players, the market is poised for significant expansion beyond its steady 2025 growth trajectory. The latest outlook highlights emerging opportunities, evolving competitive dynamics, and long-term revenue potential shaping the future of the industry.
Key Strategic Developments 2025-2026:
✅ May 2026: AbbVie advanced development of next-generation biologics targeting inflammatory bowel disease and rheumatoid arthritis to strengthen its immunology treatment portfolio.
✅ April 2026: Johnson & Johnson expanded commercialization strategies for biologic therapies focused on psoriasis and ulcerative colitis to increase global patient access and treatment adoption.
✅ March 2026: Pfizer increased investments in monoclonal antibody research and biologic manufacturing capabilities to support growing demand for precision immunology therapies.
✅ February 2026: Roche accelerated clinical development activities for biologics targeting autoimmune and inflammatory diseases using advanced antibody engineering technologies.
✅ January 2026: Amgen strengthened its inflammatory disease biologics pipeline through expanded R&D initiatives focused on cytokine inhibition and immune-response modulation.
✅ December 2025: Novartis enhanced biologics production capacity and expanded strategic collaborations to support next-generation therapies for chronic inflammatory conditions.
✅ November 2025: Eli Lilly advanced biologic drug innovation for dermatology and autoimmune disorders by integrating precision medicine and targeted immune therapies.
✅ October 2025: Sanofi increased focus on biologic therapies for inflammatory diseases through investments in immunology research and expansion of global clinical trial programs.
How Our Market Research Process Works:
The global Inflammatory Diseases Biologics Market research report delivers strategic intelligence built through a robust blend of primary insights and extensive secondary research. The study provides a deep analysis of critical market forces shaping the industry, including regulatory developments, competitive positioning, evolving demand patterns, and historical market performance. It further highlights breakthrough technologies, innovation trends, and advancements across connected industries influencing the future of Inflammatory Diseases Biologics adoption. The report also uncovers high-growth opportunities, investment potential, market risks, and key operational challenges, enabling businesses to make faster, data-driven decisions in an increasingly competitive landscape.
Funding/M&A/partnerships 2025-2026:
• May 2026: UCB agreed to acquire Candid Therapeutics for up to US$2.2 billion to strengthen its autoimmune and inflammatory disease biologics pipeline.
• May 2026: Gyre Therapeutics completed the acquisition of Cullgen to expand its inflammatory and fibrosis-focused biologics portfolio.
• January 2026: Eli Lilly announced the acquisition of Ventyx Biosciences to advance therapies targeting inflammatory-mediated diseases.
• January 2026: BioCryst Pharmaceuticals completed the acquisition of Astria Therapeutics to expand its hereditary angioedema biologics portfolio.
• January 2026: GSK agreed to acquire RAPT Therapeutics for approximately US$2.2 billion to strengthen its immunology and inflammatory disease pipeline.
Unlock & Get Full 360° Best Strategic Report: https://www.datamintelligence.com/buy-now-page?report=inflammatory-diseases-biologics-market?kb
Japan: Recent Industry Developments
✅ March 2026: Takeda Pharmaceutical Company accelerated biologics research targeting inflammatory bowel disease and immune-mediated disorders.
✅ February 2026: Chugai Pharmaceutical Co., Ltd. expanded development of antibody-based therapies for rheumatoid arthritis and systemic inflammatory conditions.
✅ January 2026: Astellas Pharma Inc. increased investment in precision biologics and immune-targeted therapeutics for chronic inflammatory diseases.
✅ December 2025: Daiichi Sankyo Company partnered with regional research institutes to advance biologic drug innovation for autoimmune and inflammatory disorders.
Major Segments Opportunity 2026:
By Drug Class: Anti-Tumor Necrosis Factor (TNF) inhibitors, Interleukin antagonists, Janus Kinase (JAK) inhibitors, Others
By Disease Indication: Rheumatoid Arthritis, Psoriasis, Inflammatory Bowel Disease, Ankylosing Spondylitis, Others
Regional Growth Intelligence for Market:
⇥ North America: 48.5% - Dominates the Inflammatory Diseases Biologics Market due to high biologics adoption, advanced healthcare infrastructure, and strong presence of leading pharmaceutical companies.
⇥ Europe: 26.4% - Growth is supported by increasing biologic drug approvals, rising autoimmune disease prevalence, and favorable reimbursement policies.
⇥ Asia-Pacific: 16.8% - Fastest-growing region driven by expanding healthcare access, rising chronic inflammatory disease cases, and increasing investments in biologics development.
⇥ Latin America: 4.6% - Market expansion is fueled by improving access to specialty therapies and growing awareness of biologic treatments.
⇥ Middle East & Africa: 3.7% - Emerging demand supported by healthcare infrastructure development and increasing adoption of advanced biologic therapies.
Request Strategic Market Customization: https://datamintelligence.com/customize/inflammatory-diseases-biologics-market?kb
Market Drivers 2026:
Increasing prevalence of autoimmune and chronic inflammatory disorders such as rheumatoid arthritis, psoriasis, inflammatory bowel disease, and ankylosing spondylitis is supporting expansion of the inflammatory diseases biologics market.
Growing utilization of monoclonal antibodies and targeted biologic therapies in clinical treatment protocols is strengthening adoption across healthcare systems.
Higher diagnosis rates and improved access to advanced biologic treatments are contributing to broader patient uptake in developed and emerging markets.
Expansion of biosimilar approvals and commercialization activities is improving treatment accessibility and supporting market penetration.
Continuous advancements in precision medicine and biomarker-based therapies are improving treatment outcomes and patient-specific therapeutic approaches.
Increasing healthcare expenditure and supportive reimbursement frameworks for biologic therapies are encouraging wider adoption in inflammatory disease management.
Ongoing clinical research focused on cytokine inhibitors, interleukin blockers, and next-generation biologics is expanding the therapeutic pipeline globally.
FAQ's:
Q1: What is the current size of the Inflammatory Diseases Biologics Market?
A: The Inflammatory Diseases Biologics Market was valued at US$ 99.06 Billion in 2024 and is projected to reach US$ 157.31 Billion by 2033
Q2: How rapidly is the Market expanding?
A: The Inflammatory Diseases Biologics Market is expected to grow at a CAGR of 5.3% during the forecast period 2025 to 2033
Get Unlimited Market Reports & Strategic Insights: https://www.datamintelligence.com/reports-subscription?kb
Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com
About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Why Are Pharmaceutical Companies Investing Heavily in Inflammatory Diseases Biologics Market 2025-2033? here
News-ID: 4517815 • Views: …
More Releases from DataM Intelligence 4 Market Research LLP
Why Is the Zero-Proof Cocktails Market Growing Rapidly 2026-2033? | Health Trend …
DataM Intelligence has unveiled its latest research study "Zero-Proof Cocktails Market Size 2026," delivering strategic intelligence designed to identify high-growth opportunities, evaluate competitive positioning, and stay ahead of rapidly evolving market trends. The report provides a comprehensive analysis of market size, revenue performance, CAGR projections, regional growth patterns, and detailed segmentation insights, along with an in-depth assessment of the key factors driving industry expansion. It also highlights emerging opportunities, investment…
WHO Declares Ebola PHEIC Accelerating Growth in the Ebola Virus Vaccine Market | …
The global Ebola Virus Vaccine market is witnessing steady and strategically important growth as governments, international health organizations, and pharmaceutical companies intensify efforts to prevent, contain, and eliminate Ebola Virus Disease outbreaks. Increasing frequency of viral hemorrhagic fever outbreaks, rising global health security funding, and continuous advancements in vaccine technologies are accelerating the development, stockpiling, and rapid deployment of Ebola vaccines across high-risk regions, particularly in Central and West Africa.
Download…
Vehicle-to-Home (V2H) Market Growth to Record US$ 19.76 billion by 2035, Top in …
global vehicle to home market reached US$ 1.39 billion in 2025 and is expected to reach US$ 19.76 billion by 2035, growing with a CAGR of 30.4% during the forecast period 2026-2035.
Get Free Sample Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/vehicle-to-home-market?kb
United States: Recent Industry Developments
✅ March 2026: Ford Motor Company expanded bidirectional charging pilot programs enabling F-150 Lightning to support Vehicle-to-Home (V2H) energy backup solutions in residential applications.
✅…
Buy Now Pay Later Market Expected to Hit US$ 238.56 Billion by 2033 as Flexible …
DataM Intelligence has released a new research report titled "Buy Now Pay Later Market Size 2026". The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size…
More Releases for Disease
Protheragen Announces Disease Model Development Services to Enhance Rare Disease …
Protheragen announced the release of its disease model development services provided to enhance rare disease research. With an increasing focus on rare diseases and the need for tailored research models, Protheragen is dedicated to providing cutting-edge solutions to support this important area of medical research.
Rare diseases, which affect a small percentage of the population, pose unique challenges for researchers due to their limited understanding and lack of available treatment options.…
Biopharmaceutical Fermentation Market 2022 | Growing Morbidity of Genetic Diseas …
According to Precision Business Insights (PBI), the latest report, the biopharmaceutical fermentation market is expected to be valued at USD 10,302.1 million in 2022, growing at a 4.7% CAGR from 2022 to 2028. The growing prevalence of chronic illness, cancer, cardiac diseases, infectious diseases, antibiotic resistance, autoimmune diseases, etc., globally causes the leaning toward biopharmaceutical products, which show promising results in the research studies. Moreover, new findings by the…
Global Inflammatory Bowel Disease (IBD) Market Key Players Analysis, Disease Ind …
Global Inflammatory Bowel Disease (IBD) Market, valued at USD 210.5 Billion in the year 2020 has been driven by factors such as the increasing prevalence of Ulcerative Colitis and Crohn’s Disease, advances in medical technology, government support for inflammatory bowel disease treatment research, and the ubiquity of anxiety and depression. Moreover, factors such as the irregular food habits, unhealthy lifestyle of people, increased level of pollution and increase in alcohol…
Moyamoya Disease Market - A Scientometric Assessment of Disease During 2018-23
Market Highlight:
Moyamoya disease (MMD) is a chronic, cerebrovascular disease characterized by progressive stenosis in the internal carotid artery and an abnormal vascular network at the base of the brain. The stroke is one of the significant symptoms of moyamoya disease, which further leads to paralysis of the face, arms, and legs, loss of speech, and temporary loss of neurologic function of body parts, visual disturbances, headaches, developmental delay, and…
Refsum Disease Industry An Overview of A New Disease - 2018
"Refsum Disease" is a genetic disorder which is inherited as an autosomal recessive trait. The condition is characterized by progressive loss of vision (retinitis pigmentosa), failure of muscle coordination (ataxia), degenerative nerve disease (peripheral neuropathy), and dry, rough, scaly skin (ichthyosis). The accumulation of fatty acid (phytanic acid) in blood plasma and tissues is the main cause of refsum disease. This occurs due to malfunction of the enzyme producing gene…
Chagas Disease (Infectious Disease) Pipeline Forecast Report, H1, 2017 [MRH]
Market Research Hub's Pharmaceutical and Healthcare latest pipeline guide Chagas Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Chagas Disease Market (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and…
